PARP2: Poly [ADP-ribose] polymerase 2
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
Poly-ADP-ribosyltransferase that mediates poly-ADP- ribosylation of proteins and plays a key role in DNA repair.
- Drugs that act on it: 5
- With a US drug page: 2
- Type: Protein
Drugs That Act on It
Approved and clinical-stage drugs ChEMBL records for this target; those with a US approval link to their page| Niraparib | Approved | Poly [ADP-ribose] polymerase 2 inhibitor | Inhibitor | — |
| Talazoparib | Approved | Poly [ADP-ribose] polymerase 2 inhibitor | Inhibitor | — |
| 2X-121 | — | Poly [ADP-ribose] polymerase 2 inhibitor | Inhibitor | — |
| Pamiparib | — | Poly [ADP-ribose] polymerase 2 inhibitor | Inhibitor | — |
| Senaparib | — | Poly [ADP-ribose] polymerase 2 inhibitor | Inhibitor | — |
Diseases Most Associated With It
Open Targets association score, 0 to 1; all associations- Ovarian cancer
- 0.60
- Neoplasm
- 0.57
- Breast cancer
- 0.56
- Ovarian carcinoma
- 0.55
- Primary peritoneal carcinoma
- 0.52
- Prostate cancer
- 0.52
- Breast neoplasm
- 0.51
- Ovarian neoplasm
- 0.50
- Peritoneum cancer
- 0.50
- Pancreatic neoplasm
- 0.49
- Fallopian tube carcinoma
- 0.49
Genes and Related Targets
Complexes and families that share a gene with this target- Genes
- PARP2
- Related
- PARP 1, 2 and 3
Drugs and mechanisms are from ChEMBL CHEMBL5366 (CC BY-SA 3.0). Gene name, function (UniProt Q9UGN5, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets